WallStreetZenWallStreetZen

NASDAQ: CERO
Cero Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CERO

Based on 2 analysts offering 12 month price targets for Cero Therapeutics Holdings Inc

Min Forecast
$30.00+1,495.74%
Avg Forecast
$45.00+2,293.62%
Max Forecast
$60.00+3,091.49%

Should I buy or sell CERO stock?

Based on 2 analysts offering ratings for Cero Therapeutics Holdings Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CERO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CERO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CERO stock forecasts and price targets.

CERO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-22
lockedlocked$00.00+00.00%2025-05-19

1 of 1

Forecast return on equity

Is CERO forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CERO forecast to generate an efficient return on assets?

Company
-503.12%
Industry
109.01%
CERO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CERO earnings per share forecast

What is CERO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$36.00
Avg 2 year Forecast
-$22.19
Avg 3 year Forecast
-$21.96

CERO revenue forecast

What is CERO's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

CERO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CERO$1.88$45.00+2,293.62%Strong Buy
GTBP$0.67N/AN/A
XRTX$0.63N/AN/A
SLXN$3.43N/AN/A
MLEC$0.63N/AN/A
View Top Biotech Stocks

Cero Therapeutics Holdings Stock Forecast FAQ

Is Cero Therapeutics Holdings Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CERO) stock is to Strong Buy CERO stock.

Out of 2 analysts, 2 (100%) are recommending CERO as a Strong Buy, 0 (0%) are recommending CERO as a Buy, 0 (0%) are recommending CERO as a Hold, 0 (0%) are recommending CERO as a Sell, and 0 (0%) are recommending CERO as a Strong Sell.

If you're new to stock investing, here's how to buy Cero Therapeutics Holdings stock.

What is CERO's earnings growth forecast for 2025-2027?

(NASDAQ: CERO) Cero Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.

Cero Therapeutics Holdings's earnings in 2025 is -$41,912,761.On average, 4 Wall Street analysts forecast CERO's earnings for 2025 to be -$43,395,557, with the lowest CERO earnings forecast at -$65,207,427, and the highest CERO earnings forecast at -$19,478,694. On average, 4 Wall Street analysts forecast CERO's earnings for 2026 to be -$26,741,843, with the lowest CERO earnings forecast at -$47,015,500, and the highest CERO earnings forecast at -$4,682,987.

In 2027, CERO is forecast to generate -$26,471,351 in earnings, with the lowest earnings forecast at -$47,015,500 and the highest earnings forecast at -$4,126,091.

What is CERO's revenue growth forecast for 2025-2027?

(NASDAQ: CERO) Cero Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.33%.

Cero Therapeutics Holdings's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast CERO's revenue for 2025 to be $0, with the lowest CERO revenue forecast at $0, and the highest CERO revenue forecast at $0. On average, 4 Wall Street analysts forecast CERO's revenue for 2026 to be $0, with the lowest CERO revenue forecast at $0, and the highest CERO revenue forecast at $0.

In 2027, CERO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CERO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CERO) forecast ROA is -503.12%, which is lower than the forecast US Biotechnology industry average of 109.01%.

What is CERO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CERO price target, the average CERO price target is $45.00, with the highest CERO stock price forecast at $60.00 and the lowest CERO stock price forecast at $30.00.

On average, Wall Street analysts predict that Cero Therapeutics Holdings's share price could reach $45.00 by Oct 22, 2026. The average Cero Therapeutics Holdings stock price prediction forecasts a potential upside of 2,293.62% from the current CERO share price of $1.88.

What is CERO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CERO) Cero Therapeutics Holdings's current Earnings Per Share (EPS) is -$66.53. On average, analysts forecast that CERO's EPS will be -$36.00 for 2025, with the lowest EPS forecast at -$54.10, and the highest EPS forecast at -$16.16. On average, analysts forecast that CERO's EPS will be -$22.19 for 2026, with the lowest EPS forecast at -$39.00, and the highest EPS forecast at -$3.89. In 2027, CERO's EPS is forecast to hit -$21.96 (min: -$39.00, max: -$3.42).

What is CERO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CERO) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.